# CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors

> **NCT03113188** · PHASE1 · COMPLETED · sponsor: **CanBas Co. Ltd.** · enrollment: 47 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** CBP501

## Key facts

- **NCT ID:** NCT03113188
- **Lead sponsor:** CanBas Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-25
- **Primary completion:** 2021-02-15
- **Final completion:** 2021-02-15
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2021-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03113188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03113188, "CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03113188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*